Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

BACKGROUND: Casirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein, blocking viral entry into host cells. We aimed to evaluate the efficacy and safety of casirivimab and imdevimab administ...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830904/
https://www.ncbi.nlm.nih.gov/pubmed/35151397
http://dx.doi.org/10.1016/S0140-6736(22)00163-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830904/
https://www.ncbi.nlm.nih.gov/pubmed/35151397
http://dx.doi.org/10.1016/S0140-6736(22)00163-5

Ejemplares similares